Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | CCR3 | P51677 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355272 | 0.86 | CACNA1G (0.42) | CCR3ACKR3CCR1HTR4 | |
| SCHEMBL3355221 | 0.79 | DRD3 (0.51) | DRD3CCR3SIGMAR1MCHR1HTR4 | |
| SCHEMBL3355275 | 0.77 | CCR1 (0.34) | CCR1 | |
| SCHEMBL3356313 | 0.77 | MEN1 (0.36) | CCR1LMNA | |
| SCHEMBL3351119 | 0.77 | PDE4B (0.41) | CCR3MCHR1 | |
| SCHEMBL3354397 | 0.76 | HTT (0.42) | — | |
| SCHEMBL3355919 | 0.75 | CACNA1G (0.36) | HTR4 | |
| SCHEMBL3355480 | 0.75 | ALDH1A1 (0.45) | LMNA | |
| SCHEMBL3355392 | 0.74 | MC4R (0.36) | CCR3CCR1LMNA | |
| SCHEMBL3358694 | 0.72 | PDE4A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR4, CCR5 | DRD3 1569/4885CCR3 5/4885SIGMAR1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.